What is Xphozah and Current Approval Status?
Xphozah (feladilimab) is an anti-CD40 ligand monoclonal antibody developed by Novartis for preventing kidney transplant rejection. FDA approved it in August 2024 for use with basiliximab, mycophenolate, and corticosteroids in adults receiving a kidney transplant from a deceased donor at increased immunological risk, defined by specific HLA antibody levels.[1] It's not approved for living donor transplants or other organs yet.
Steps to Expand Xphozah's Label to Living Donor Transplants
Novartis is pursuing label expansion via a supplemental Biologics License Application (sBLA). Key steps include:
- Submit sBLA with data from the Phase 3 FEDBACK trial (NCT04552686), showing non-inferiority to tacrolimus-based regimens in living donor transplants.[2]
- FDA review under priority review (granted October 2024), targeting PDUFA date April 19, 2025.[3]
- Potential advisory committee meeting if FDA requests; none announced yet.
Path to Broader Indications Like Heart or Liver Transplants
Ongoing Phase 3 trials (e.g., IMPHANT for heart transplants, TRANSLATE for liver) provide data for future sBLAs:
1. Complete enrollment and topline results (expected 2025-2026).[4]
2. File sBLA post-positive data, leveraging organ-specific endpoints like biopsy-proven rejection rates.
3. Address immunogenicity risks, as CD40L antibodies have black-box warnings for thromboembolism—mitigated by trial designs excluding high-risk patients.[1]
Regulatory Timelines and Exclusivity
- Orphan drug exclusivity until August 2029; pediatric exclusivity could extend to 2030.[5]
- No major patent challenges listed on DrugPatentWatch; key U.S. patents expire 2038-2041. [6][https://www.drugpatentwatch.com/p/tradename/XPHOZAH]
- EU approval possible via EMA in 2025 if parallel filings succeed.
Competitive Landscape and Barriers
Xphozah differentiates from calcineurin inhibitors (e.g., tacrolimus) by sparing kidney function, but expansion faces:
- Competitors like Horizon's voclosporin or Hansa Biopharma's imlifidase.
- Risks: Trial failures (e.g., higher thrombosis in early CD40L trials) or manufacturing scale-up delays.
- Pricing: List price ~$250,000/year; expansion could increase market to $2B+ if multi-organ approved.[7]
Sources
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761312s000lbl.pdf
[2] Novartis Press Release: https://www.novartis.com/news/media-releases/novartis-submits-sbla-feladilimab-first-class-medicine-prevent-kidney-transplant-rejection
[3] FDA PDUFA Calendar
[4] ClinicalTrials.gov: NCT04552686, NCT05126711
[5] FDA Orange Book
[6] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/XPHOZAH
[7] Evaluate Pharma estimates